ATLANTA – Transcatheter aortic valve replacement (TAVR) with a supra-annular, self-expanding valve (SEV) was noninferior to TAVR with an intra-annular, balloon-expandable valve (BEV) with regard to clinical outcomes, and superior concerning bioprosthetic valve dysfunction, through 12 months in patients with symptomatic, severe aortic stenosis who have small aortic annuli, the SMART Trial shows.